The Hormel Institute, University of Minnesota’s, George Aslanidi, PhD, has published research that could lead to improved access to personalized treatment for patients with genetic diseases. With more than 7,000 genetic diseases with limited treatments available, the need for personalized approaches to disease treatment is ever present.
In the past few years, the U.S. Food and Drug Administration has approved several genetic drugs based on the Adeno-associated virus (AAV). AAV is a virus that can be designed to deliver DNA to targeted cells. However, the lack of a personalized approach to find the most appropriate type of AAV for treatment means these treatments aren’t effective for all people who need it.
Dr. Aslanidi and his team have developed and validated a novel laboratory test used to find
and measure the amount of a specific substance that can help to identify which AAVs may best
meet eligibility requirements for patients with genetic diseases to enroll in appropriate clinical
Dr. Aslanidi plans to conduct further studies to continue to validate the test and work with clinical doctors to match patients’ information with particular drugs formulation needed for treatment.
The article “Multiplexing AAV Serotype-Specific Neutralizing Antibodies in Preclinical Animal Models and Humans” was published in the journal Biomedicines. The full article is available here: https://www.mdpi.com/2227-9059/11/2/523.